Clinical trials: Insulin Sensitivity/Resistance
- Condition Insulin Sensitivity/Resistance
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Type 2 Diabetes Mellitus
Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus
This is an 8-week, single centre, randomized, parallel-group, double-blind, placebo-controlled Phase IV study to evaluate the effect of dapagliflozin on tissue specific insulin sensitivity in patients with Type 2 diabetes mellitus
- Trial name
- DERISC (NCT02426541)
- Testing
- Dapagliflozin
- Where
- Finland
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes
The purpose of this study was to evaluate, in patients with Type 2 Diabetes Mellitus, whether Canakinumab can lower Glycosylated hemoglobin / hemoglobin A1c (HbA1c) and/or peak glucose levels in response to an oral glucose…
- Trial name
- NCT00605475
- Testing
- Canakinumab, Metformin
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 231 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 2, Skeletal Muscle Insulin Sensitivity
Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.
The purpose of this study is to investigate the effects of 5 weeks treatment with dapagliflozin in type 2 diabetes patients on how the hormone insulin acts on sugar uptake in muscles.
- Trial name
- DAPAMAAST (NCT03338855)
- Testing
- Dapagliflozin
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- AstraZeneca
Hypertension, Concurrent Obesity
Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects
This study investigated the effects of LCZ696 on insulin sensitivity, lipolysis, and oxidative metabolism in obese hypertensive subjects.
- Trial name
- NCT01631864
- Testing
- LCZ696, amlodipine
- Where
- 3 sites in Germany, Netherlands
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals